Energetic consequences of substances currently used or recommended for long-term treatment of chronic heart failure

Basic Res Cardiol. 1991:86 Suppl 1:107-12.

Abstract

Vasodilators have been shown to improve hemodynamics of the failing heart as a short-term effect, and to decrease mortality as a long-term result. We, therefore, studied the effects of vasodilators and inotropic agents on myocardial mechanics and energetics in patients with congestive heart failure New York Heart Association (NYHA) classes II-III. In these patients, who underwent routine heart catheterization, myocardial oxygen consumption was measured using the argon method, and LV pressure and geometry were obtained from LV angiography using a Millar microtipped catheter. All data were analyzed for one single heart beat. The best correlation was found between MVO2/beat and the systolic stress-time integral which considers LV pressure, LV wall thickness, and LV geometry. The relation between MVO2/beat and peak systolic wall stress was less relevant. No correlation was found between MVO2/beat and pressure-volume work, dP/dtmax, and mean velocity of circumferential fiber shortening. The intravenous application of nitroprusside and the ACE-inhibitor benazepril decreased both the systolic stress-time integral and the myocardial oxygen consumption in proportion to each other, indicating unchanged economy of myocardial contraction. In contrast, beta 1-agonists and phosphodiesterase inhibitors increased myocardial oxygen consumption independently of changes in the stress-time integral. In conclusion, vasodilators decrease LV pressure and chamber size and thereby proportionally reduce MVO2/beat. The reduction of energy needed for myocardial contraction may partially explain the long-term effects of the ACE-inhibitors and combinations of vasodilators. Pure inotropic substances, especially beta 1-agonists, increase myocardial oxygen consumption with only minor changes of systolic stress-time integral.(ABSTRACT TRUNCATED AT 250 WORDS)

MeSH terms

  • Benzazepines / pharmacology
  • Cardiotonic Agents / pharmacology*
  • Energy Metabolism / drug effects
  • Enoximone
  • Heart Failure / drug therapy*
  • Heart Failure / metabolism
  • Heart Failure / physiopathology
  • Hemodynamics / drug effects
  • Humans
  • Imidazoles / pharmacology
  • Myocardium / metabolism
  • Nitroprusside / pharmacology
  • Oxygen Consumption / drug effects
  • Propanolamines / pharmacology
  • Vasodilator Agents / pharmacology*
  • Xamoterol

Substances

  • Benzazepines
  • Cardiotonic Agents
  • Imidazoles
  • Propanolamines
  • Vasodilator Agents
  • Nitroprusside
  • Xamoterol
  • Enoximone
  • benazepril